Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)

During the Trading Day
19.52 -0.06 / -0.31%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
19.52 0.00 / 0.00%
 
Volume: 28.8K
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$546.6M

Company Description

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It is engaged in the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases. The company's lead product, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. The company was founded by David I. Scheer and William H. Lewis on February 4, 2005 and is headquartered in Cambridge, MA.

Contact Information

Aegerion Pharmaceuticals, Inc.
101 Main Street
Cambridge Massachusetts 02142
P:(617) 500-7867
Investor Relations:
(857) 242-5024

Employees

Shareholders

Other institutional74.99%
Mutual fund holders47.63%
Individual stakeholders38.66%

Top Executives

Sandy D. SmithChief Executive Officer & Independent Director
Gregory D. PerryChief Financial Officer
Mark SumerayChief Medical Officer
Anne Marie CookSecretary, Senior Vice President & General Counsel
William AndrewsSenior Vice President-Business Development